Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
about
Bile acids for non-alcoholic fatty liver disease and/or steatohepatitisHereditary hemochromatosis in the post-HFE eraNon-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude.Advanced MRI methods for assessment of chronic liver diseaseLiver fat volume fraction quantification with fat and water T1 and T 2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T.Quantification of the triglyceride fatty acid composition with 3.0 T MRI.Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modelingFat and water magnetic resonance imaging.Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice.Independent estimation of T*2 for water and fat for improved accuracy of fat quantificationPediatric Metabolic Syndrome: Pathophysiology and Laboratory AssessmentMetabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis.Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis.On the performance of T2* correction methods for quantification of hepatic fat content.Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver diseaseSilymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activationBax inhibition protects against free fatty acid-induced lysosomal permeabilization.Liver fat is reproducibly measured using computed tomography in the Framingham Heart Study.PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosisThe metabolic syndrome and nonalcoholic fatty liver disease in childrenQuantification of liver fat in mice: comparing dual-echo Dixon imaging, chemical shift imaging, and 1H-MR spectroscopy.Hepatitis C virus infection and nonalcoholic steatohepatitisA simple Indian diabetes risk score could help identify nondiabetic individuals at high risk of non-alcoholic fatty liver disease (CURES-117)Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent.Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.Role of NCAN rs2228603 polymorphism in the incidence of nonalcoholic fatty liver disease: a case-control study.Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.Magnetic resonance spin-spin relaxation time estimation in a rat model of fatty liver disease.The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis.Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.The effect of β-caryophyllene on nonalcoholic steatohepatitis.[Model of experimental nonalcoholic steatohepatitis from use of methionine and choline deficient diet].Relationship between cerebral arterial pulsatility and carotid intima media thickness in diabetic and non-diabetic patients with non-alcoholic fatty liver disease.Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis.Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
P2860
Q24243149-6B65504F-8AC5-43C2-A0AF-7359A206544FQ24646056-0C2FC81B-7B83-4E6D-949C-92F3401591C8Q30464853-F6686279-5A5C-484C-BEAC-41854B83B594Q30478601-14502533-7421-4120-87F5-556632C1A9B1Q30616960-8E700C08-3CFC-4C36-8DA2-B28919F29D7EQ30842915-CA117C37-214B-422B-9A26-20000CE5CFD9Q33453637-BECB9547-0A06-4988-8CBD-0837374FEFADQ33520271-73D338BB-AA24-46F7-858C-C8F84B20BC23Q33520636-280EE753-A5BB-449D-B105-E6BD9017EA75Q33550434-F1F2D809-ADB1-4178-9ACD-95EFDC26F4A9Q33551642-5F99FD39-60C4-435A-889E-3425F8D07A7DQ33631151-68A20186-449B-407C-808E-70D6C22252E0Q33851563-7F60724E-056D-4CFE-BC29-C504D2DDFF2BQ33857534-02183B47-E5B0-4255-8380-2AB1BDFAAE37Q33928955-58F91D47-C53C-4AFE-9D97-DE22C09B85C6Q34297858-42469920-F77E-4547-8E6F-41B2FAB0F0A9Q34449757-29973292-5A99-47FD-B220-DE6F0F3967CEQ34665604-B7F70304-5B2E-4728-A0A3-6A88ADFC97FDQ34674340-76E54B41-2EAD-4EE1-BCA9-A7F711DA48C9Q34759018-500436A3-8FC6-4DBD-8C5C-9CB508C16C59Q34773966-72BABF6C-F6DB-48AA-AD8D-A6BAD386AEB2Q34778237-2F6C6E06-0EA0-4749-8F6F-D860603E045DQ35212883-AB6E5FFC-F4C1-400A-BD9A-6A09D7A38C55Q36179898-E3C6C16B-425A-4F82-B857-236BB8D67DB9Q36605826-A33112C5-A403-4F76-843F-F51B61109164Q37197345-FA346FF4-EB75-4136-B7A4-8ABF62CA269EQ37405449-C6C3A5F4-ABB8-4731-8202-234056F4BDB9Q37442575-F0460378-5827-4F0F-AE1E-1F6F4A31C8C1Q37699734-46BF8AEC-1013-4BDB-883F-F9AC9F41BEC1Q37863133-3D9F2C49-69A6-428D-9A2C-4FD4D64258E3Q37873715-62E9C16C-D82B-4A74-BF61-AB4944CC657AQ38714500-FE45F2C8-DAA4-46AE-9AA9-4B6E5B9FB6E1Q43045643-989ED903-941D-423C-AB40-985BE0911AA6Q45031991-5D97803E-E883-4272-8209-05BE9411E968Q45790201-87C7CA93-6268-45B3-82B1-A735243B7335Q45998455-8BBEC07A-9D94-43E4-869B-11781C4E8E78Q46066324-155F213E-0F98-47F9-98CC-FD4B06D58155Q46256534-2FEAC434-82A1-4898-B281-EE54F2A3E313Q46924821-B1EFC26A-4853-40AD-B6C7-5D004D4D18A0Q48242025-6CF7C86F-0CDD-4C93-B559-C5F5DD9700AE
P2860
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
@ast
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
@en
type
label
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
@ast
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
@en
prefLabel
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
@ast
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
@en
P1476
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
@en
P2093
Brent A Neuschwander-Tetri
Stephen A Harrison
P304
861-79, ix
P356
10.1016/J.CLD.2004.06.008
P577
2004-11-01T00:00:00Z